TICKERNOMICS Sign up
Last Update: 2024-03-28 02:11:50
BELITE BIO INC ( BLTE ) https://belitebio.com
43.50USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
BLTE
50.00%
SPY
32.74%
BLTE
0.00%
SPY
92.93%
BLTE
0.00%
SPY
224.41%
BLTE
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1188.23
1181.82
0.02
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-37.81
0.00
22.51
-1.42
0.00
-33.15
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-87.94
-88.11
0.00
Other Earnings and Cash Flow Stats:
BELITE BIO INC ( BLTE ) Net Income TTM ($MM) is -27.02
BELITE BIO INC ( BLTE ) Operating Income TTM ($MM) is -27.10
BELITE BIO INC ( BLTE ) Owners' Earnings Annual ($MM) is 0.00
BELITE BIO INC ( BLTE ) Current Price to Owners' Earnings ratio is 0.00
BELITE BIO INC ( BLTE ) EBITDA TTM ($MM) is -27.08
BELITE BIO INC ( BLTE ) EBITDA Margin is 0.00%
Capital Allocation:
BELITE BIO INC ( BLTE ) has paid 0.00 dividends per share and bought back -7.338954 million shares in the past 12 months
BELITE BIO INC ( BLTE ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
BELITE BIO INC ( BLTE ) Interest-bearing Debt ($MM) as of last quarter is 0
BELITE BIO INC ( BLTE ) Annual Working Capital Investments ($MM) are -3
BELITE BIO INC ( BLTE ) Book Value ($MM) as of last quarter is 52
BELITE BIO INC ( BLTE ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
BELITE BIO INC ( BLTE ) has 6 million in cash on hand as of last quarter
BELITE BIO INC ( BLTE ) has 0 million of liabilities due within 12 months, and long term debt 0 as of last quarter
BELITE BIO INC ( BLTE ) has 27 common shares outstanding as of last quarter
BELITE BIO INC ( BLTE ) has 0 million USD of preferred stock value
Academic Scores:
BELITE BIO INC ( BLTE ) Altman Z-Score is 147.42 as of last quarter
BELITE BIO INC ( BLTE ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
BELITE BIO INC ( BLTE ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of BELITE BIO INC ( BLTE ) for the amount of $ on
64.03% of BELITE BIO INC ( BLTE ) is held by insiders, and 0.63% is held by institutions
BELITE BIO INC ( BLTE ) went public on 2022-04-29
Other BELITE BIO INC ( BLTE ) financial metrics:
FCF:-9.22
Unlevered Free Cash Flow:-32.85
EPS:-1.60
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-82.85
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About BELITE BIO INC ( BLTE ) :
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.